Actively Recruiting
Artificial Intelligence Guided Echocardiographic Screening of Rare Diseases (EchoNet-Screening)
Led by Cedars-Sinai Medical Center · Updated on 2025-06-27
300
Participants Needed
1
Research Sites
288 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Despite rapidly advancing developments in targeted therapeutics and genetic sequencing, persistent limits in the accuracy and throughput of clinical phenotyping has led to a widening gap between the potential and the actual benefits realized by precision medicine. Recent advances in machine learning and image processing techniques have shown that machine learning models can identify features unrecognized by human experts and more precisely/accurately assess common measurements made in clinical practice. The investigators have developed an algorithm, termed EchoNet-LVH, to identify cardiac hypertrophy and identify patients who would benefit from additional screening for cardiac amyloidosis and will prospectively evaluate its accuracy in identifying patients whom would benefit from additional screening for cardiac amyloidosis.
CONDITIONS
Official Title
Artificial Intelligence Guided Echocardiographic Screening of Rare Diseases (EchoNet-Screening)
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients who have a high suspicion for cardiac amyloidosis by AI algorithm
You will not qualify if you...
- Patients who decline to be seen at specialty clinic
- Patients who have passed away
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Cedars-Sinai Medical Centre (Los Angeles)
Los Angeles, California, United States, 90048
Actively Recruiting
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here